Abstract

The proposed Mayo Alzheimer's Disease Research Center (ADRC) will build upon the experience of the previously funded Mayo Alzheimer's Disease Center (P30) and the new faculty at Mayo Jacksonville, FL and the Mayo Scottsdale, AZ to address research questions in aging and Alzheimer's disease (AD). The ADRC will consist of five cores: Administrative Core, Clinical and Research Support Core, Neuropathology and Genetics Core, Neuroimaging Core and Education and Information Transfer Core, and two projects: Project 1: """"""""Cytoskeletal Pathology in the Neurodegeneration of AD,""""""""Project """"""""The contribution of Leukoaraisosis to Cognitive Impairment in Aging and Alzheimer's Disease."""""""" The Center will address several scientific themes including neuroepidemiology of dementia and AD, the boundary between normal aging and AD, and predictors of cognitive impairment in asymptomatic persons. New faculty appointments in Mayo Jacksonville in the basic science of amyloid processing, tau, genetics and antibody development will complement the clinical and epidemiology expertise in the remainder of the Center. Investigators in Scottsdale will add functional imaging studies in at-risk subjects to pursue the scientific themes of the Center. The proposed ADRC will extend the productivity of the existing Alzheimer's Disease Center and develop new insights into aging and AD.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
3P50AG016574-05S1
Application #
6788404
Study Section
Special Emphasis Panel (ZAG1)
Program Officer
Phelps, Creighton H
Project Start
1999-05-01
Project End
2004-04-30
Budget Start
2003-08-15
Budget End
2004-04-30
Support Year
5
Fiscal Year
2003
Total Cost
$71,620
Indirect Cost

  Institution

Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905

  Publications

Vassilaki, Maria; Aakre, Jeremiah A; Syrjanen, Jeremy A et al. (2018) Mediterranean Diet, Its Components, and Amyloid Imaging Biomarkers. J Alzheimers Dis 64:281-290
Zhao, Na; Liu, Chia-Chen; Van Ingelgom, Alexandra J et al. (2018) APOE ?2 is associated with increased tau pathology in primary tauopathy. Nat Commun 9:4388
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Mordes, Daniel A; Prudencio, Mercedes; Goodman, Lindsey D et al. (2018) Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients. Acta Neuropathol Commun 6:55
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Zhan, Yiqiang; Clements, Mark S; Roberts, Rosebud O et al. (2018) Association of telomere length with general cognitive trajectories: a meta-analysis of four prospective cohort studies. Neurobiol Aging 69:111-116
Lowe, Val J; Bruinsma, Tyler J; Min, Hoon-Ki et al. (2018) Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. Alzheimers Dement (Amst) 10:210-216
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Sassi, Celeste; Nalls, Michael A; Ridge, Perry G et al. (2018) Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3. Neurobiol Aging 66:179.e17-179.e29
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021

Showing the most recent 10 out of 1014 publications